All In Biotech

Drug Trial Radar · NCT04309474

A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

Nov 9, 2020

Primary completion

Apr 18, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab and assess change in neurologic function in participants following an acute ischemic stroke. Elezanumab is an investigational drug being developed for the treatment of acute ischemic stroke. This 52-week study is "double-blinded', which means that neither the participants nor the study doctors will know who will be given elezanumab and who will be given placebo (does not contain treatment drug). Participants will be assigned to one of two groups, called treatment arms. Participants in one arm will receive elezanumab and participants in the other arm will receive placebo. There is a 1 in 2 chance that participants will be assigned to placebo. Approximately 120 subjects will be enrolled in 45 sites worldwide. Participants will be randomized to elezanumab or placebo by intravenous (IV) infusion within 24 hours of "last known normal" (time when the participant was last known to be without signs and symptoms of the current stroke) and every 4 weeks thereafter for 48 weeks for a total of 13 doses. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of elezanumab will be checked by medical assessments, blood tests, evaluation of side effects, and completion of questionnaires.

Conditions

  • Acute Ischemic Stroke

Interventions

  • ElezanumabDrug

    Intravenous (IV) infusion

  • PlaceboDrug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment PeriodTime frame: Day 1 through Week 52

Locations

42 sites in 6 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona /ID# 214957

    Phoenix, Arizona

  • Long Beach Medical Center /ID# 217210

    Long Beach, California

  • Georgetown University Hospital /ID# 216481

    Washington D.C., District of Columbia

  • Duplicate_Mayo Clinic /ID# 217567

    Jacksonville, Florida

  • Northwestern University Feinberg School of Medicine /ID# 215047

    Chicago, Illinois

  • Duplicate_University of Kentucky Chandler Medical Center /ID# 216394

    Lexington, Kentucky

  • University of Louisville Hospital /ID# 217569

    Louisville, Kentucky

  • Tufts Medical Center /ID# 215053

    Boston, Massachusetts

  • University of Mississippi Medical Center /ID# 217587

    Jackson, Mississippi

  • St. Luke's Marion Bloch Neuroscience Institute /ID# 215028

    Kansas City, Missouri

  • Washington University-School of Medicine /ID# 214526

    St Louis, Missouri

  • Hackensack Univ Med Ctr /ID# 218200

    Hackensack, New Jersey

  • University of New Mexico School of Medicine /ID# 216827

    Albuquerque, New Mexico

  • Columbia University Medical Center /ID# 215122

    New York, New York

  • UH Cleveland Medical Center /ID# 215372

    Cleveland, Ohio

  • Cleveland Clinic Main Campus /ID# 214635

    Cleveland, Ohio

  • The Ohio State University /ID# 215036

    Columbus, Ohio

  • Lehigh Valley Health Network /ID# 242446

    Allentown, Pennsylvania

  • Thomas Jefferson University Hospital /ID# 215469

    Philadelphia, Pennsylvania

  • University of Texas Health Science Center at Houston /ID# 215018

    Houston, Texas

  • Baylor Scott & White Medical Center- Temple /ID# 225513

    Temple, Texas

  • University of Virginia /ID# 215757

    Charlottesville, Virginia

  • Duplicate_Royal North Shore Hospital /ID# 239083

    St Leonards, New South Wales, Australia

  • The Royal Melbourne Hospital /ID# 240178

    Parkville, Victoria, Australia

  • University of Alberta Hospital /ID# 218370

    Edmonton, Alberta, Canada

  • Hamilton General Hospital /ID# 218970

    Hamilton, Ontario, Canada

  • Fukuoka University Chikushi Hospital /ID# 240629

    Chikushino-shi, Fukuoka, Japan

  • Fukuoka Wajiro Hospital /ID# 239810

    Fukuoka, Fukuoka, Japan

  • National Hospital Organization Kagoshima Medical Center /ID# 240021

    Kagoshima, Kagoshima-ken, Japan

  • Nagano Municipal Hospital /ID# 240622

    Nagano, Nagano, Japan

  • Yamaguchi Grand Medical Center /ID# 239892

    Hohu-shi, Yamaguchi, Japan

  • Duplicate_Pusan National University Hospital /ID# 233769

    Busan, Busan Gwang Yeogsi, South Korea

  • Duplicate_CHA University Bundang Medical Center /ID# 233503

    Seongnam-si, Gyeonggido, South Korea

  • Seoul National University Hospital /ID# 233473

    Seoul, Seoul Teugbyeolsi, South Korea

  • Samsung Medical Center /ID# 234241

    Seoul, Seoul Teugbyeolsi, South Korea

  • Hospital Universitario Vall de Hebron /ID# 217087

    Barcelona, Spain

  • Hospital Universitario La Paz /ID# 216380

    Madrid, Spain

  • Hospital Universitario Virgen Macarena /ID# 216382

    Seville, Spain

  • Hospital Universitario Virgen del Rocio /ID# 216339

    Seville, Spain

  • Complejo Hospitalario Universitario A Coruña /ID# 230080

    A Coruña, A Coruna, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.